An update to the ICER lupus nephritis model evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States (AMCP 2024) - Apr 9, 2024 - Abstract #D19; "The AURORA 1 study found the addition of VCS to mycophenolate mofetil and low-dose glucocorticoids yielded significant reductions in proteinuria. Economic modeling of LN evaluated the cost-effectiveness of VCS. Following the inclusion of updated data in the model, VCS was found to be cost-effective, substantially below the ICER published willingness to pay threshold of $150,000/QALY. These results are consistent with the original ICER evaluation with VCS continuing to be a cost-effective treatment for LN."
Cost effectiveness • HEOR • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Atencio V1; Lee E2; Flauto R3; Birardi V3; Kennedy L4
|